Related Experiment Videos
Diagnosis of familial amyloidotic polyneuropathy by recombinant DNA techniques
Abstract:
An amino acid substitution of Met for Val at position 30 of plasma prealbumin is known to be closely related to heredo-familial amyloidotic polyneuropathy(FAP). As a first step in development of a direct method for diagnosis of the disease, cDNA for normal human prealbumin was cloned and its nucleotide sequence was determined. Our results showed that the nucleotide substitution responsible for the Val----Met change results in formation of new restriction sites for BalI and NsiI. By Southern blot hybridization analysis, the expected restriction sites were actually detected in the prealbumin locus of patients. Thus, a method was developed for diagnosis of the disease presymptomatically and prenatally.
Insights
A genetic mutation in plasma prealbumin causes hereditary amyloid polyneuropathy (FAP). Researchers developed a diagnostic method by identifying specific DNA changes, enabling early and prenatal FAP detection.
Area of Science:
- Genetics
- Molecular Biology
- Neurology
Background:
- Heredo-familial amyloidotic polyneuropathy (FAP) is linked to a specific amino acid substitution (Valine to Methionine at position 30) in plasma prealbumin.
- Early diagnosis is crucial for managing FAP, but direct diagnostic methods are limited.
Purpose of the Study:
- To develop a direct diagnostic method for hereditary amyloidotic polyneuropathy (FAP).
- To identify the specific nucleotide substitution responsible for the Val-30-Met prealbumin variant.
Main Methods:
- Cloning and sequencing of cDNA for normal human prealbumin.
- Utilizing restriction fragment length polymorphism (RFLP) analysis with BalI and NsiI restriction enzymes.
- Southern blot hybridization to detect specific restriction sites in patient DNA.
Main Results:
- The nucleotide substitution causing the Val-30-Met change creates new restriction sites for BalI and NsiI.
- Southern blot analysis confirmed the presence of these specific restriction sites in the prealbumin locus of FAP patients.
- This genetic marker allows for the identification of individuals carrying the FAP-associated mutation.
Conclusions:
- A direct diagnostic method for FAP has been established based on identifying specific restriction enzyme sites.
- This method enables presymptomatic diagnosis in at-risk individuals.
- Prenatal diagnosis of FAP is now feasible, allowing for early intervention and genetic counseling.